person · Reporting owner
Longsworth Todd Christopher
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | General Counsel | March 08, 2022 | March 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date March 08, 2022 · Filed March 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 62,462 |
Reported balance
After 2022-03-08 transaction · row 1
1 source rowRow 1 · 2022-03-08 · Sale · Disposed 2,339 · Balance 62,462 F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2018 Filed Feb 26, 2018 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionRestricted Stock Units · Derivative | 21,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-013433 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,333 Underlying: Ordinary Shares · 21,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.expiration_date: Fully vested as of the date hereof. Read SEC document |
| February 22, 2018 Filed Feb 26, 2018 17:14 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 21,667 | $21.55 | $466,923.85 |
DisclosureSEC source: 0001209191-18-013433 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,665 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:29 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 11,630 | $0.00 Strike: $6.72 | $0.00 |
DisclosureSEC source: 0001209191-18-006215 · doc4.xml · derivative · entry 3 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,152 Underlying: Ordinary Shares · 82,782 shares Expires 2022-04-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested and exercisable as of the date hereof. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:29 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 11,630 | $24.00 | $279,120.00 |
DisclosureSEC source: 0001209191-18-006215 · doc4.xml · nonDerivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,998 F1 · shares: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by Mr. Longsworth. Read SEC document |
| January 29, 2018 Filed Jan 31, 2018 16:29 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 11,630 | $6.72 | $78,153.60 |
DisclosureSEC source: 0001209191-18-006215 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,628 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 08, 2018 Filed Jan 10, 2018 16:09 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 166 | $15.05 | $2,497.47 |
DisclosureSEC source: 0001209191-18-003112 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,998 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of July 1, 2017 through December 31, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on July 3, 2017. Read SEC document |
| July 05, 2017 Filed Jul 7, 2017 16:48 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOrdinary Shares | 2,810 | $6.67 | $18,751.13 |
DisclosureSEC source: 0001209191-17-044407 · doc4.xml · nonDerivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,832 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January 1, 2017 through June 30, 2017. This transaction is also exempt under Rule 16b-3(c). F2 · shares: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on January 3, 2017. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:06 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Unit · Derivative | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005222 · doc4.xml · derivative · entry 2 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Ordinary Shares · 65,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share. F3 · derivative.exercise_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Longsworth's continued employment through such dates. F3 · derivative.expiration_date: One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Longsworth's continued employment through such dates. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:06 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 227,500 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0000899243-17-005222 · doc4.xml · derivative · entry 1 Longsworth Todd Christopher · CIK 0001693530 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,500 Underlying: Ordinary Shares · 227,500 shares Expires 2027-02-22 F1 · derivative.exercise_date: Options to buy 227,500 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Longsworth's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.